Tzu Chi Medical Journal
Volume 23, Issue 4 , Pages 115-118 , December 2011

Analysis of pathogens and susceptibility in cancer patients with febrile neutropenia and bacteremia: Experience in a single institution in eastern Taiwan

  • Kuan-Po Huang

      Affiliations

    • Department of Oncology and Hematology, Buddhist Tzu Chi General Hospital, Taichung Branch, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Oncology and Hematology, Buddhist Tzu Chi General Hospital, Taichung Branch, 88, Section 1, Feng-Xing Road, Tanzi Dist, Taichung, Taiwan. Tel.: +886 4 36060666; fax: +886 4 36065928.
    • ,
  • Tso-Fu Wang

      Affiliations

    • Department of Oncology and Hematology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • ,
  • Sung-Chao Chu

      Affiliations

    • Department of Oncology and Hematology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • ,
  • Yi-Feng Wu

      Affiliations

    • Department of Oncology and Hematology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • ,
  • Rou-Yun Wang

      Affiliations

    • Department of Oncology and Hematology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • ,
  • Ruey-Ho Kao

      Affiliations

    • Department of Oncology and Hematology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • Department of Oncology, Tzu Chi University, Hualien, Taiwan

Received 2 June 2011 ,Revised 20 July 2011 ,Accepted 7 September 2011.

References 

  1. Bal AM, Gould IM. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. Int J Antimicrob Agents. 2007;29:501–509
  2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  3. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(Suppl. 4):S240–S245
  4. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on Gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–494
  5. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–1110
  6. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis. 2001;33:1295–1301
  7. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International antimicrobial therapy cooperative group of the European organization for research and treatment of cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto infection program. Antimicrob Agents Chemother. 1996;40:1108–1115
  8. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23:795–805
  9. Chiu HH, Huang LM, Lee PI, Lee CY. Bacteremia and fungemia in hematological and oncological children with neutropenic fever: two-year study in a medical center. J Microbiol Immunol Infect. 1998;31:101–106
  10. Lai HP, Hsueh PR, Chen YC, Lee PI, Lu CY, Lu MY, et al. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan. J Microbiol Immunol Infect. 2003;36:197–202
  11. Chen CY, Tang JL, Hsueh PR, Yao M, Huang SY, Chen YC, et al. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematologic malignancy. J Formos Med Assoc. 2004;103:526–532
  12. Wang FD, Jang TN, Liu CY. Infections in febrile granulocytopenic patients: clinical features and pathogens. J Formos Med Assoc. 1996;95:410–413
  13. Pei SN, Wang MC, Huang EY. Febrile neutropenia in patients with acute leukemia following chemotherapy: a retrospective review. J Intern Med. 2006;17:106–113
  14. Infectious Disease Society of Taiwan; Hematology Society of Taiwan; Medical Foundation in Memory Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee’s Research Foundation for Pediatric Infectious Diseases and Vaccine . Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005;38:455–457
  15. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266
  16. McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressure. Antimicrob Agents Chemother. 2001;45:3084–3091
  17. Sheng WH, Chen YC, Wang JT, Chang SC, Luh KT, Hsieh WC. Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn Microbiol Infect Dis. 2002;43:141–147
  18. Baurn HV, Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection. 2000;28:278–281

PII: S1016-3190(11)00092-9

doi: 10.1016/j.tcmj.2011.09.002

Tzu Chi Medical Journal
Volume 23, Issue 4 , Pages 115-118 , December 2011

Article Tools